Does Treatment of Impaired Glucose Tolerance Improve Cardiovascular Outcomes in Patients with Previous Myocardial Infarction?
| Autor: | Yoshiyuki Nagai, Yoshihiko Kinoshita, Sumio Mizuno, Shunichi Yoda, Takahisa Yamada, Isao Morii, Masashi Fujita, Yasuyuki Maruyama, Takahiro Muroya, Hiroshi Suzuki, Reimin Sawada, Takayoshi Yamanouchi, Abc investigators, Susumu Fujino, Mitsuru Tsujimoto, Masataka Sata, Kazuki Fukui, Yasuharu Nakama, Takanori Ohkusa, Toyoaki Murohara, Yuji Hashimoto, Hiroyuki Takase, Tetsuya Ishikawa, Hajime Yamaguchi, Nobuyuki Ohte, Masafumi Kitakaze, Hideki Hayashi, Shuntaro Ikeda, Kazuo Satake, Hideo Himeno, Tomohiko Shigemasa, Koichi Tamita, Jiyoong Kim, Hiroyasu Uzui, Yorihiko Higashino, Masanori Asakura, Tsutomu Endo, Tetsuro Ueda, Makoto Nakahama, Tatsuya Nunohiro, Osamu Doi, Toshimitsu Hamasaki, Takaaki Shiono, Kengo Tsukahara, Tohru Kohno, Makoto Shimizu, Satoru Sakagami, Yukiko Morita, Shinji Koba, Yoshikazu Hiasa, Hiroshi Asanuma, Jitsuo Higaki |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Male
medicine.medical_specialty medicine.medical_treatment Myocardial Infarction Kaplan-Meier Estimate 030204 cardiovascular system & hematology Impaired glucose tolerance 03 medical and health sciences 0302 clinical medicine Japan Internal medicine Voglibose Glucose Intolerance Clinical endpoint Secondary Prevention Medicine Humans Hypoglycemic Agents Pharmacology (medical) Glycoside Hydrolase Inhibitors 030212 general & internal medicine Myocardial infarction Prospective Studies Prospective cohort study Aged Pharmacology business.industry Unstable angina Percutaneous coronary intervention General Medicine Middle Aged medicine.disease Discontinuation Treatment Outcome Cardiovascular Diseases Cardiology Female Cardiology and Cardiovascular Medicine business Inositol medicine.drug |
| Zdroj: | Cardiovascular drugs and therapy. 31(4) |
| ISSN: | 1573-7241 |
| Popis: | We evaluated the effects of an alpha-glucosidase inhibitor, voglibose, on cardiovascular events in patients with a previous myocardial infarction (MI) and impaired glucose tolerance (IGT). This prospective, randomized, open, blinded-endpoint study was conducted in 112 hospitals and clinics in Japan in 3000 subjects with both previous MI and IGT receiving voglibose (0.6 mg/day, n = 424) or no drugs (n = 435) for 2 years. The Data and Safety Monitoring Board (DSMB) recommended discontinuation of the study in June 2012 after an interim analysis when the outcomes of 859 subjects were obtained. The primary endpoint was cardiovascular events including cardiovascular death, nonfatal MI, nonfatal unstable angina, nonfatal stroke, and percutaneous coronary intervention/coronary artery bypass graft. Secondary endpoints included individual components of the primary endpoint in addition to all-cause mortality and hospitalization due to heart failure. The age, ratio of males, and HbA1C were 65 vs. 65 years, 86 vs. 87%, and 5.6 vs. 5.5% in the groups with and without voglibose, respectively. Voglibose improved IGT; however, Kaplan–Meier analysis showed no significant between-group difference with respect to cardiovascular events [12.5% with voglibose vs. 10.1% without voglibose for the primary endpoint (95% confidence interval, 0.82–1.86)]; there were no significant differences in secondary endpoints. Although voglibose effectively treated IGT, no additional benefits for cardiovascular events in patients with previous MI and IGT were observed. Voglibose may not be a contributing therapy to the secondary prevention in patients with MI and IGT. Clinicaltrials.gov number: NCT00212017 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink